ABSTRACT
BACKGROUND: Hereditary angioedema with C1 inhibitor deficiency (HAE-C1INH) is a rare disease characterized by swelling episodes. It affects quality of life (QOL) and can be fatal when the upper airways are involved. Treatment is individualized, with therapeutic options including on-demand treatment (ODT) and short- and long-term prophylaxis (STP, LTP). However, available guidelines are not always clear about the selection of treatment, the goals of treatment, or how achievement of these goals is assessed. OBJECTIVE: To review available evidence for the management of HAE-C1INH and build a Spanish expert consensus to steer management towards a treat-to-target approach, while addressing some of the less clear aspects of the Spanish guidelines. METHODS: We reviewed the literature on the treat-to-target management of HAE-C1INH, focusing on treatment selection and goals and the tools available to assess whether the goals have been achieved. We discussed the literature based on clinical experience and drew up 45 statements on undefined management aspects. A panel of 53 HAE experts validated the statements through a 2-round Delphi process. RESULTS: The goals for ODT and STP are to minimize the morbidity and mortality of attacks and to prevent attacks caused by known triggers, respectively, while the main goal of LTP is to decrease the rate, severity, and duration of attacks. Furthermore, when prescribing, clinicians should consider the reduction in adverse effects, while increasing patient QOL and satisfaction. Appropriate instruments for assessing achievement of treatment goals are also indicated. CONCLUSIONS: We provide recommendations on previously unclear aspects of HAE-C1INH management with ODT, STP, and LTP, focusing on clinical and patient-oriented goals.
Subject(s)
Angioedemas, Hereditary , Humans , Angioedemas, Hereditary/drug therapy , Quality of Life , Consensus , Complement C1 Inhibitor Protein/therapeutic useABSTRACT
Background: Hereditary angioedema with C1 inhibitor deficiency (HAE-C1INH) is a rare disease characterized by swelling episodes. It affects quality of life (QOL) and can be fatal when the upper airways are involved. Treatment is individualized, with therapeutic options including on-demand treatment (ODT) and short- and long-term prophylaxis (STP, LTP). However, available guidelines are not always clear about the selection of treatment, the goals of treatment, or how achievement of these goals is assessed. Objective: To review available evidence for the management of HAE-C1INH and build a Spanish expert consensus to steer management towards a treat-to-target approach, while addressing some of the less clear aspects of the Spanish guidelines. Methods: We reviewed the literature on the treat-to-target management of HAE-C1INH, focusing on treatment selection and goals and the tools available to assess whether the goals have been achieved. We discussed the literature based on clinical experience and drew up 45 statements on undefined management aspects. A panel of 53 HAE experts validated the statements through a 2-round Delphi process. Results: The goals for ODT and STP are to minimize the morbidity and mortality of attacks and to prevent attacks caused by known triggers, respectively, while the main goal of LTP is to decrease the rate, severity, and duration of attacks. Furthermore, when prescribing, clinicians should consider the reduction in adverse effects, while increasing patient QOL and satisfaction. Appropriate instruments for assessing achievement of treatment goals are also indicated.Conclusions: We provide recommendations on previously unclear aspects of HAE-C1INH management with ODT, STP, and LTP, focusing on clinical and patient-oriented goals (AU)
Subject(s)
Humans , Angioedemas, Hereditary/drug therapy , Complement C1 Inactivator Proteins/therapeutic use , Quality of Life , ConsensusSubject(s)
Allergens/adverse effects , Antineoplastic Agents/adverse effects , Biological Factors/therapeutic use , Drug Hypersensitivity/diagnosis , Immunization/methods , Antineoplastic Agents/therapeutic use , Biological Factors/adverse effects , Carboplatin/adverse effects , Carboplatin/therapeutic use , Female , Humans , Male , Oxaliplatin/adverse effects , Oxaliplatin/therapeutic use , Pilot Projects , Skin Tests , Taxoids/adverse effects , Taxoids/therapeutic useSubject(s)
Humans , Male , Female , Allergens , Antineoplastic Agents/adverse effects , Biological Factors/adverse effects , Drug Hypersensitivity/diagnosis , Desensitization, Immunologic/methods , Retrospective Studies , Pilot Projects , Carboplatin/adverse effects , Oxaliplatin/adverse effects , Skin Tests , Taxoids/adverse effectsABSTRACT
The disease caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ie, coronavirus disease 2019 (COVID-19), has become a global pandemic since it was first reported in Wuhan, China in December 2019. Its severe clinical manifestations, which often necessitate admission to intensive care units, and high mortality rate represent a therapeutic challenge for the medical community. To date, no drugs have been approved for its treatment, and various therapeutic options are being assayed to address the pathophysiological processes underlying the clinical manifestations experienced by patients. New and old drugs administered as monotherapy or in combination to immunologically compromised patients may favor the development of adverse drug reactions, including drug hypersensitivity reactions, which must be identified and managed accordingly. Given the lack of herd immunity and the high rate of viral contagion, new cases are expected to emerge in the coming months. Thus, the probability of more adverse reactions or even new clinical manifestations may increase in parallel. Allergists must receive updated information on these treatments, as well as on the management of possible drug hypersensitivity reactions.
Subject(s)
COVID-19 Drug Treatment , Drug Hypersensitivity/diagnosis , Drug Hypersensitivity/etiology , Antiviral Agents/adverse effects , Antiviral Agents/therapeutic use , COVID-19/complications , COVID-19/immunology , COVID-19/pathology , Cytokines/antagonists & inhibitors , Diagnosis, Differential , Humans , Hypersensitivity, Delayed/diagnosis , Hypersensitivity, Delayed/etiology , Hypersensitivity, Immediate/diagnosis , Hypersensitivity, Immediate/etiology , Immunologic Factors/adverse effects , Immunologic Factors/therapeutic use , SARS-CoV-2ABSTRACT
The disease caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ie, coronavirus disease 2019 (COVID-19), has become a global pandemic since it was first reported in Wuhan, China in December 2019. Its severe clinical manifestations, which often necessitate admission to intensive care units, and high mortality rate represent a therapeutic challenge for the medical community. To date, no drugs have been approved for its treatment, and various therapeutic options are being assayed to address the pathophysiological processes underlying the clinical manifestations experienced by patients. New and old drugs administered as monotherapy or in combination to immunologically compromised patients may favor the development of adverse drug reactions, including drug hypersensitivity reactions, which must be identified and managed accordingly. Given the lack of herd immunity and the high rate of viral contagion, new cases are expected to emerge in the coming months. Thus, the probability of more adverse reactions or even new clinical manifestations may increase in parallel. Allergists must receive updated information on these treatments, as well as on the management of possible drug hypersensitivity reactions
La enfermedad causada por el nuevo Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), se ha expandido en forma de pandemia global desde su inicio en Wuhan (China) en diciembre de 2019. La aparición de formas clínicas graves asociadas a la necesidad de ingreso en unidades de Cuidados Intensivos, con un alto índice de letalidad, ha supuesto un reto terapéutico para la comunidad médica. Actualmente no hay ningún fármaco aprobado para su tratamiento y se están ensayando diversas opciones terapéuticas para abordar los procesos fisiopatológicos responsables de las manifestaciones clínicas que experimentan los pacientes. Tanto el uso de viejos como de nuevos principios activos como tratamiento único o en combinación, en pacientes inmunológicamente comprometidos, puede favorecer la aparición de efectos adversos, entre ellos reacciones de hipersensibilidad de mecanismo inmunológico, que habrá que saber identificar y manejar correctamente. Es de prever que, en los próximos meses, dada la falta de inmunidad comunitaria y el elevado índice de contagiosidad del virus, sigan surgiendo nuevos casos y, con ello, la probabilidad de que aparezcan más reacciones adversas o incluso nuevas manifestaciones clínicas. Es importante que los alergólogos estén al día de las opciones terapéuticas que se están utilizando, así como de sus posibles reacciones adversas, inclusive reacciones de hipersensibilidad y cómo manejarlas
Subject(s)
Humans , Coronavirus Infections/drug therapy , Pneumonia, Viral/drug therapy , Pandemics , Antiviral Agents/adverse effects , Antiviral Agents/therapeutic use , Drug HypersensitivitySubject(s)
Amoxicillin-Potassium Clavulanate Combination/adverse effects , Anti-Allergic Agents/adverse effects , Cetirizine/adverse effects , Chemical and Drug Induced Liver Injury/diagnosis , Chemical and Drug Induced Liver Injury/etiology , beta-Lactamase Inhibitors/adverse effects , Adult , Biomarkers , Female , Humans , Liver Function Tests , Severity of Illness Index , UltrasonographyABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , Amoxicillin-Potassium Clavulanate Combination/adverse effects , Anti-Allergic Agents/adverse effects , Cetirizine/adverse effects , Chemical and Drug Induced Liver Injury/diagnosis , Chemical and Drug Induced Liver Injury/etiology , beta-Lactamase Inhibitors/adverse effects , Biomarkers/blood , Liver Function Tests , Severity of Illness Index , UltrasonographyABSTRACT
Allergy to egg is highly frequent in childhood. In general, children allergic to egg react principally to the ingestion of egg white. Egg yolk contains various proteins but the major allergens are contained in egg white. The principal allergens are ovalbumin, ovomucoid, ovotransferrin, and lysozyme. These proteins have been sequenced. In some cases, a relationship between type I hypersensitivity with respiratory symptoms due to bird antigens and allergy to egg yolk has been described. This association is known as bird-egg syndrome, which is caused by sensitization to chicken serum albumin (alpha -livetin) and is characterized by the development of respiratory and gastrointestinal symptoms after egg intake or after contact with bird antigens. The initial symptoms are usually asthma with or without rhinoconjunctivitis due to contact with birds. Individuals first become sensitized to bird proteins (feathers, excrement, serum and meat) and subsequently develop egg allergy. Although bird-egg syndrome has been described principally in adults, especially in women, it can also affect children in whom the syndrome presents certain differentiating characteristics in relation to the more common sensitization to egg white. Gastrointestinal and respiratory symptoms are more common than cutaneous symptoms and sensitization to egg yolk is more frequent than that to egg white. In children with allergy to birds and egg, egg allergy is usually more persistent; tolerance is not always achieved and develops later. Sensitization to other aeroallergens is also greater in individuals with allergy to birds and egg. Sensitization to egg sometimes precedes respiratory sensitization to bird proteins, a process known as bird-egg syndrome. By way of example, the case of a child who clinically presented bird-egg syndrome is presented at the end of this review.
Subject(s)
Egg Proteins/adverse effects , Eggs/adverse effects , Food Hypersensitivity/etiology , Adult , Allergens/adverse effects , Allergens/immunology , Animals , Bronchial Spasm/etiology , Chickens , Child , Child, Preschool , Cross Reactions , Desensitization, Immunologic , Egg Proteins/immunology , Female , Food Hypersensitivity/diagnosis , Food Hypersensitivity/therapy , Humans , Infant , Male , Respiratory Hypersensitivity/etiology , Vomiting/etiologyABSTRACT
La alergia al huevo es muy frecuente en la infancia. En general, los alérgicos al huevo reaccionan principalmente a la ingesta de la clara. La yema de huevo tiene diversas proteínas pero la clara contiene los alergenos mayores. Los alergenos principales son: ovoalbúmina, ovomucoide, ovotransferrina y lisozima. Estas proteínas han podido ser secuenciadas. Se ha descrito, en algunos casos, una relación entre la hipersensibilidad tipo I con síntomas respiratorios por antígenos de aves y la alergia alimentaria a yema de huevo. A esta asociación se la conoce como síndrome ave-huevo. Este síndrome es causado por sensibilización a la albúmina sérica de pollo ( -livetina) y se caracteriza por el desarrollo de síntomas respiratorios y digestivos tras la ingestión de huevos o tras el contacto con antígenos de aves.. Los síntomas iniciales suelen ser de asma con o sin rinocon- juntivitis por contacto con aves. Primero se sensibilizan a proteínas aviares (plumas, excrementos, suero y carne) y, posteriormente, desarrollan hipersensibilidad alimentaria a huevo. A pesar de que el síndrome ave-huevo se ha descrito sobre todo en adultos con predominio en mujeres, también puede afectar a niños y en ellos se presentan unas características diferenciales respecto a la sensibilización a la clara de huevo más habitual. Predominan los síntomas digestivos y respiratorios sobre los cutáneos y la sensibilización a yema es mayor que la de la clara. En los niños con alergia a aves y huevo, la alergia al huevo suele ser más persistente; no siempre se consigue una tolerancia y en todo caso esta aparece más tarde. La sensibilización a otros neumoalergenos también es superior en el grupo de alérgicos a aves y huevo. A veces, la sensibilización a huevo precede a la sensibilización inhalatoria a proteínas aviares y entonces se habla de síndrome huevo-ave. Al final de la revisión se presenta a modo de ejemplo el caso clínico de un niño que clínicamente presenta un síndrome huevo-ave (AU)
Allergy to egg is highly frequent in childhood. In general, children allergic to egg react principally to the ingestion of egg white. Egg yolk contains various proteins but the major allergens are contained in egg white. The principal allergens are ovalbumin, ovomucoid, ovotransferrin, and lysozyme. These proteins have been sequenced. In some cases, a relationship between type I hypersensitivity with respiratory symptoms due to bird antigens and allergy to egg yolk has been described. This association is known as bird-egg syndrome, which is caused by sensitization to chicken serum albumin (α -livetin) and is characterized by the development of respiratory and gastrointestinal symptoms after egg intake or after contact with bird antigens. The initial symptoms are usually asthma with or without rhinoconjunctivitis due to contact with birds. Individuals first become sensitized to bird proteins (feathers, excrement, serum and meat) and subsequently develop egg allergy.Although bird-egg syndrome has been described principally in adults, especially in women, it can also affect children in whom the syndrome presents certain differentiating characteristics in relation to the more common sensitization to egg white. Gastrointestinal and respiratory symptoms are more common than cutaneous symptoms and sensitization to egg yolk is more frequent than that to egg white. In children with allergy to birds and egg, egg allergy is usually more persistent; tolerance is not always achieved and develops later. Sensitization to other aeroallergens is also greater in individuals with allergy to birds and egg. Sensitization to egg sometimes precedes respiratory sensitization to bird proteins, a process known as bird-egg syndrome. By way of example, the case of a child who clinically presented bird-egg syndrome is presented at the end of this review (AU)
Subject(s)
Animals , Child, Preschool , Child , Adult , Male , Infant , Female , Humans , Respiratory Hypersensitivity , Bronchial Spasm , Chickens , Cross Reactions , Desensitization, Immunologic , Allergens , Egg Proteins , Eggs , Food Hypersensitivity , VomitingABSTRACT
We report the cases of 2 patients diagnosed as having primula dermatitis. Both patients were housewives who had been exposed to primula plants. Although only one related her clinical manifestations with looking after plants, the symptoms of both remitted when contact with primula was avoided. The diagnosis was carried out with a patch test concentration of 0.01% primin pet. As primula dermatitis has variable clinical manifestations that can not easily be related to contact allergy, we emphasize the need to include synthetic primin in our standard patch test series.
